Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CD8+ TiLs and T-cell exhaustion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 25, 2024 9:27pm

82 Views

Post# 36057709

RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion

" Unlike other approved anti-PD-L1 antibodies, avelumab has a native Fc region that retains FcγR binding capability."

Avelumab is cleared faster and has a shorter half-life than other anti-PD-L1 antibodies, such as atezolizumab and durvalumab, which appears to negatively impact T cell clones expansion. Consequently the addition of the PD-L1 inhibitor avelumab, unlike atezolizumab, eliminated pre-existing TIL expansion in the blood and reduced pelareorep's clinical activity.

https://stockhouse.com/news/press-releases/2024/05/24/oncolytics-biotech-xae-asco-abstracts-highlight-pelareorep-s-potential-in

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – June 26, 2024